NCT03805932 2026-05-19Moxetumomab Pasudotox-tdfk (Lumoxiti(TM)) and Either Rituximab (Rituxan(R)) or Ruxience for Relapsed Hairy Cell LeukemiaNational Institutes of Health Clinical Center (CC)Phase 1 Active not recruiting18 enrolled 15 charts